Tissue transglutaminase (tTG or TG2) is a calcium-dependent enzyme that catalyzes protein cross-linking through isopeptide bond formation between glutamine and lysine residues. In healthy tissue, it stabilizes the extracellular matrix and facilitates wound healing, but in genetically susceptible individuals (HLA-DQ2/DQ8+), it becomes the primary autoantigen in celiac disease by deamidating gliadin peptides and forming immunogenic complexes that trigger autoimmune intestinal destruction.
Think of tTG as a molecular tailor working in the body's repair shop. Normally, this tailor uses its special calcium-powered needle to sew proteins together—stitching glutamine residues to lysine residues, creating strong cross-links that hold the extracellular matrix fabric tight during wound healing. It's essential maintenance work that happens constantly beneath the surface.
But when gluten arrives in the intestine of someone with the wrong genetic locks (HLA-DQ2/DQ8), this helpful tailor makes a catastrophic modification: it strips away a chemical group from gliadin (deamidation), changing the peptide's charge from neutral to negative. This is like altering a garment's color to bright red—suddenly it catches the attention of passing immune security guards (antigen-presenting cells). The modified gliadin now fits perfectly into the HLA-DQ2/DQ8 display cases on these cells, triggering alarm bells.
Worse still, the tailor itself gets caught in the crossfire. Because tTG physically binds to gliadin while modifying it, the immune system starts producing antibodies against both the modified gliadin AND the tailor itself. The tailor becomes labeled as "enemy collaborator." This dual targeting—attacking both the foreign invader and the body's own repair enzyme—is the hallmark of celiac autoimmunity. The once-helpful repair worker is now hunted, and the intestinal lining loses its ability to heal.
tTG is a 78 kDa multifunctional enzyme requiring millimolar concentrations of Ca²⁺ (1-5 mM) for activation. Its catalytic mechanism proceeds through two distinct pathways:
1. Normal Cross-Linking Function:
Ca²⁺ binding → conformational change exposing active site (Cys277) → nucleophilic attack on glutamine γ-carboxamide → acyl-enzyme intermediate → lysine ε-amino group attacks → isopeptide bond (Gln-Lys cross-link) formation → stabilized ECM proteins (fibronectin, collagen, fibrinogen)
2. Pathological Deamidation in Celiac Disease:
graph TD
A[Gliadin peptides enter lamina propria] --> B[tTG binds gliadin via transglutaminase domain]
B --> C["Ca²⁺ activation in inflammatory environment"]
C --> D["Deamidation: Glutamine → Glutamic acid"]
D --> E[Negatively charged gliadin peptides]
E --> F[Enhanced binding to HLA-DQ2/DQ8 on APCs]
F --> G["CD4+ T cell activation"]
G --> H[Anti-gliadin T cell response]
G --> I[Anti-tTG antibody production by B cells]
I --> J[IgA anti-tTG forms immune complexes]
J --> K["Complement activation → intestinal damage"]
K --> L[Villous atrophy and crypt hyperplasia]
H --> L
The deamidation reaction specifically targets glutamine residues at positions where gliadin peptides (particularly 33-mer α-gliadin) have QXP motifs (Q = glutamine, X = any amino acid, P = proline). This increases the net negative charge, creating optimal anchor residues for HLA-DQ2 (binding preference for negatively charged P4, P6, P7 pockets) and HLA-DQ8 (preference for P1, P9 positions).
Molecular Details:
- Active site: Cys277-His335-Asp358 catalytic triad
- Deamidation reaction: R-CO-NH₂ + H₂O → R-COOH + NH₃
- Km for gliadin peptides: ~50-100 μM (higher in inflammatory conditions)
- tTG activity increases 10-100 fold in celiac lesions due to elevated intracellular Ca²⁺ from barrier dysfunction
- Forms covalent tTG-gliadin complexes recognized as neo-epitopes
- IgA anti-tTG antibodies target conformational epitopes and catalytic domain
The enzyme also undergoes S-nitrosylation at Cys277 (reducing activity) and phosphorylation by PKA (modulating subcellular localization), but inflammatory conditions with oxidative stress promote active, denitrosylated forms.
Understanding tTG is foundational for cPNI practitioners managing celiac disease and non-celiac gluten sensitivity. Anti-tTG IgA antibodies have 95-98% sensitivity and 94-97% specificity for active celiac disease, making them the gold-standard serological test. However, the test requires ongoing gluten exposure (≥10g/day for 6-8 weeks minimum)—stopping gluten prematurely causes antibody levels to drop, yielding false negatives.
Metamodel Connections:
This exemplifies Metamodel 1 (Evolutionary Mismatch): modern wheat varieties with higher gluten content and altered gliadin epitope frequency create unprecedented antigenic load. Agricultural intensification introduced novel gluten structures our immune systems never encountered during evolution. The selfish immune system perspective shows how anti-tTG antibodies, initially targeting foreign gliadin, expand to attack self-tissue—a case of collateral damage where immune self-preservation (destroying infected/damaged enterocytes) inadvertently destroys repair mechanisms.
Clinical Thresholds:
- IgA anti-tTG >20 U/mL (varies by assay): high suspicion for celiac disease
- IgA anti-tTG >100 U/mL: nearly diagnostic (>95% PPV for Marsh 3 lesions)
- Monitor IgA deficiency (occurs in 2-3% of celiac patients)—if total IgA <0.2 g/L, use IgG anti-tTG or anti-DGP instead
- Post-gluten-free diet: antibodies decline with t½ ~4-6 months, but may persist 12+ months in severe cases
Intervention Implications:
- Strict gluten elimination remains the only definitive treatment
- Larazotide acetate (zonulin inhibitor) targets upstream intestinal permeability, potentially reducing tTG exposure to gliadin
- Enzyme supplementation (ALV003, AN-PEP) aims to digest gliadin before tTG interaction—still experimental
- Address intestinal permeability drivers: NSAID use, chronic stress (↑ cortisol → ↑ zonulin), gut dysbiosis, alcohol
- Support barrier repair: glutamine (5-10g/day), zinc carnosine (75-150mg BID), vitamin D (maintain >75 nmol/L), omega-3 fatty acids (↑ resolvins, ↓ inflammatory priming)
- Monitor for cross-reactive foods where molecular mimicry may occur: casein (A1 beta-casein shares epitopes with α-gliadin), coffee, dairy
- Screen for associated autoimmune conditions (type 1 diabetes, Hashimoto's thyroiditis)—antigen spreading is common
The tTG case illustrates a critical cPNI principle: enzyme-substrate complexes can become autoantigens when post-translational modifications create neo-epitopes. This mechanism extends beyond celiac disease—similar processes occur in rheumatoid arthritis (citrullination via peptidylarginine deiminases creating ACPA targets) and diabetes (GAD65 antibodies).
- Molecular weight: 78 kDa (687 amino acids)
- Requires 1-5 mM Ca²⁺ for enzymatic activity; inactive in resting cells (Ca²⁺ ~100 nM)
- Catalytic triad: Cys277-His335-Asp358
- Ubiquitously expressed but highest levels in endothelial cells, fibroblasts, enterocytes, and keratinocytes
- Multiple cellular forms: cytosolic (repair/apoptosis), membrane-bound (adhesion/migration), extracellular (matrix stabilization)
- In celiac disease, 95-98% of patients have IgA anti-tTG antibodies (if IgA-sufficient)
- Deamidation increases gliadin peptide binding affinity to HLA-DQ2/DQ8 by 50-100 fold
- Also called TG2 (transglutaminase 2) to distinguish from other family members (TG1/keratinocyte TG, TG3/epidermal TG, TG4-7)
- Forms 1:1 covalent complexes with gliadin that persist for days in tissue
- Anti-tTG antibodies deposit in intestinal mucosa, mesenteric lymph nodes, and (in dermatitis herpetiformis) in dermal-epidermal junction
- GTP-bound form has reduced transamidase activity but enhanced protein disulfide isomerase and kinase functions
- Inhibited by cystamine, monodansylcadaverine, and physiologically by S-nitrosylation (NO donors)
- Knockout mice (Tgm2⁻/⁻) are viable but show impaired wound healing and reduced fibrin stabilization
- Coeliac disease — tTG is the primary autoantigen; anti-tTG IgA is the diagnostic hallmark of active celiac disease
- Gliadin — tTG deamidates gliadin glutamine residues to glutamic acid, creating negatively charged epitopes that enhance immunogenicity 50-100 fold
- Gluten — dietary gluten provides the substrate (gliadin) that tTG modifies, triggering the celiac cascade in genetically susceptible individuals
- HLA-DQ2 — tTG-deamidated gliadin peptides bind with high affinity to HLA-DQ2 pockets (present in 90-95% of celiac patients)
- HLA-DQ8 — alternative HLA molecule (present in 5-10% of celiac patients) that also preferentially binds negatively charged, tTG-modified gliadin
- Molecular Mimicry — tTG exemplifies how enzyme-substrate complexes can trigger autoimmunity when shared epitopes confuse immune recognition
- intestinal permeability — elevated zonulin in celiac disease increases paracellular permeability, allowing gliadin to reach lamina propria where tTG is active
- Zonulin — intestinal permeability regulator upregulated by gliadin exposure; blocking zonulin reduces gliadin access to submucosal tTG
- Calcium — millimolar Ca²⁺ is obligatory for tTG enzymatic activity; inflammatory conditions with barrier breach increase intracellular Ca²⁺
- antibodies — anti-tTG IgA antibodies are the most sensitive/specific celiac biomarker; IgG anti-tTG used in IgA deficiency
- IgA — the predominant antibody isotype in anti-tTG responses; IgA deficiency (2-3% of celiac patients) requires IgG testing
- autoimmune disease — celiac disease is prototypic organ-specific autoimmunity where enzyme modification of dietary antigen creates self-reactivity
- wound healing — tTG's normal physiological role is cross-linking ECM proteins (fibronectin, collagen) during tissue repair
- Glutamine — amino acid substrate for tTG's deamidation reaction (Gln → Glu) and cross-linking donor (Gln-Lys bonds)
- CD4+ T cells — recognize tTG-modified gliadin presented by HLA-DQ2/DQ8 on APCs, driving adaptive immune response in celiac disease
- gut barrier — tTG activity is concentrated in lamina propria; barrier dysfunction allows gliadin penetration to tTG-rich submucosal zones
- Citrullination — analogous post-translational modification in rheumatoid arthritis (PAD4 converts arginine to citrulline, creating ACPA autoantigens)
- Inflammation — inflammatory cytokines (TNF-α, IFN-γ) upregulate tTG expression and activity, amplifying celiac pathology
- Vitamin D — vitamin D deficiency (<50 nmol/L) associated with increased celiac disease risk; VDR polymorphisms affect disease susceptibility
- CXCR3 — chemokine receptor on intraepithelial lymphocytes; its ligands are upregulated by anti-tTG-mediated epithelial damage in celiac disease
- Intestinal permeability — chronic elevation from anti-tTG immune complex deposition perpetuates gliadin entry and autoimmune amplification
- Type 1 diabetes — shares HLA-DQ2/DQ8 genetic susceptibility with celiac disease; 8-10% of T1D patients develop celiac disease (antigen spreading)
- Hashimoto's thyroiditis — another common comorbid autoimmune condition in celiac patients; gluten elimination may reduce thyroid antibody titers
- Module 1: Introduced in context of wheat germ agglutinin, zonulin, and gluten sensitivity mechanisms; tTG as autoantigen in barrier dysfunction
- Module 4: Detailed coverage as primary autoantigen in celiac disease immunopathology; anti-tTG antibodies as diagnostic markers